BAC
Bank of America Corporation
BAC has the edge over CCAP overall, supported by stronger valuation and stronger fundamentals.
CCAP
Crescent Capital BDC, Inc.
CCAP trails on the overall score without a compensating advantage in the available component scores.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
CCAP Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Healthy | |
| N/A | |
| N/A |
CCAP's profitability is currently healthy, but its revenue is weak. Free cash flow and net leverage aren't meaningful measures for financial services companies like CCAP.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC has the edge over CCAP in the historical PE scenario, which offers more potential upside but is not a forecast.
CCAP PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.8x | $6.07 | -40% |
| Forward | 7x | $10.10 | — |
| Fair | 7.4x | $7.78 | -23% |
| Expensive | 9.4x | $9.89 | -2.1% |
| Current | 9.7x | $10.10 | — |
Historical ranges are pointers, not guarantees.
CCAP's PE is in its expensive range at 9.7x. On analysts' estimates for next year's earnings, today's price would be 7.0x, in its fair range.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over CCAP on the outlook, with more favorable earnings and revenue expectations.
CCAP Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Decline | |
| Decline | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect CCAP's earnings and revenue to decline, with profitability weakening.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over CCAP on earnings, with more consistent year-over-year improvement.
CCAP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.45 | +38% |
| Q3 2026 | $1.05 | -45% |
| Q2 2026 | $1.23 | -41% |
| Q1 2026 | $1.78 | -20% |
| Q4 2025 | $1.81 | -25% |
| Q3 2025 | $1.91 | -23% |
| Q2 2025 | $2.09 | -14% |
| Q1 2025 | $2.22 | -7.1% |
| Q4 2024 | $2.40 | +4.3% |
CCAP's earnings per share have fallen from their peak: $1.05 over the past year, against $5.34 in early 2021.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the stronger quarterly revenue trend. Revenue is up 6.7% for BAC versus down 82% for CCAP.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
CCAP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2022 | $6.6M | -82% |
| Q1 2022 | $23M | -3.1% |
| Q4 2021 | $18.7M | -49% |
| Q3 2021 | $22.9M | -43% |
| Q2 2021 | $35.8M | -38% |
| Q4 2020 | $36.5M | +220% |
CCAP's revenue has slid since its 2020 peak: $7M last quarter, down 82% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2022 | -9.2% | -104 points |
| Q1 2022 | 71% | -21 points |
| Q4 2021 | 77% | -18 points |
| Q3 2021 | 75% | -21 points |
| Q2 2021 | 95% | -3.4 points |
| Q1 2021 | 92% | N/A |
| Q4 2020 | 96% | +16 points |
| Q3 2020 | 97% | N/A |
CCAP's operating margin was −9.2% last quarter, down 104 points from the same quarter a year ago, near the bottom of its range since 2019.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC has the edge over CCAP on cash flow, with more consistent year-over-year improvement.
CCAP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $24.4M | -21% |
| Q2 2026 | $9.8M | -73% |
| Q1 2026 | -$23.8M | -$8.7M |
| Q4 2025 | $22.6M | +$25.5M |
| Q3 2025 | $30.8M | -34% |
| Q2 2025 | $36.4M | +$61.1M |
| Q1 2025 | -$15.1M | -138% |
| Q4 2024 | -$2.9M | -108% |
CCAP's free cash flow was $33M over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like CCAP.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over CCAP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
CCAP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -8.5K shares |
| 1 year | -0.6% | -215K shares |
| 3 years | -0.6% | -216K shares |
| 5 years | +31% | +8.7M shares |
| Available history | +41% | +10.6M shares |
CCAP has 37M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $667,000 |
| Q1 2026 | $1M |
| Q4 2025 | $1M |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
CCAP spent $3M buying back its own shares over the past year.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
CCAP Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2022 | 13.4x | High |
| Q1 2022 | 7.6x | High |
| Q4 2021 | 7.1x | High |
| Q3 2021 | 5.1x | High |
| Q2 2021 | 3.8x | Elevated |
| Q1 2021 | 3.2x | Elevated |
| Q4 2020 | 8.5x | High |
| Q3 2020 | 14.2x | High |
CCAP's net debt is about 13 years of its operating earnings (EBITDA), up from 3.8 years a year ago. Net leverage isn't a meaningful measure for financial services companies like CCAP.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
CCAP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.3 | Neutral |
| Stochastic | 34.5 | Neutral |
CCAP's weekly RSI is 45 (neutral) and its Stochastic is 35 (neutral).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
CCAP PE vs Financial Services Sector
| Metric | CCAP | Sector median | Relative |
|---|---|---|---|
| PE | 9.7x | 13x | 26% below |
| PE % | 85 | 65 | 20 pts above |
CCAP has the edge over BAC on valuation relative to its sector.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
CCAP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.25 | 9.2% above |
| 20 week MA | $10.2 | 0.6% below |
| 50 week MA | $12.0 | 15% below |
| 100 week MA | $14.0 | 28% below |
| 200 week MA | $15.4 | 34% below |
CCAP has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 34% below its 200-week average.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has the edge over CCAP on returns for 2026, with the stronger performance.
CCAP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $17.1 | $15.0 | -12% |
| 2021 | $15.0 | $18.0 | +20% |
| 2022 | $18.0 | $13.1 | -27% |
| 2023 | $13.1 | $17.4 | +32% |
| 2024 | $17.4 | $19.8 | +14% |
| 2025 | $19.8 | $14.7 | -25% |
| 2026 YTD | $14.7 | $10.1 | -31% |
CCAP has finished lower in three of the last six years. It's down 31% so far in 2026.